Skip to content

Azenta

US · AZTA #2893 by market cap Listed 1970
35.89 -3.46 -8.79%
Live - 5344 symbols - heartbeat 79s ago · 2026-10-08 08:29
Pre-market 35.75 -0.39%
After-hours 36.32 +1.20%
Overnight 35.89 0.00%
Market cap
1.57B
P/B
1.04
EPS
-1.22
Reader sentiment Are you bullish or bearish on AZTA?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 1.14 In line with history 52nd percentile
5-year average 1.56 · #7 of 51 in Medical Instruments & Supplies
P/E ratio -14.63 In line with history 48th percentile
5-year average -31.12 · forward 67.47
P/S ratio 2.81 Cheap vs history 30th percentile
5-year average 5.21 · forward 2.70 · #27 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
Azenta (AZTA) 1.57B -13.34 1.04 0.00%
Intuitive Surgical (ISRG) 146.44B 47.54 8.06 0.00%
Becton Dickinson & Co (BDX) 49.07B 54.43 2.01 2.33%
ResMed (RMD) 31.78B 21.67 4.83 1.06%
Medline (MDLN) 31.10B 67.27 2.69 0.00%
Alcon (ALC) 30.45B 48.09 1.41 0.56%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value41.08 Economic moatNone UncertaintyHigh

Trading 14.5% below Morningstar's fair value estimate.

Fair value

Azenta Inc earns a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 4% discount to our quantitative fair value estimate of $41.08 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's balance sheet increases our estimated fair value. Low leverage mitigates financial risk, potentially boosting a firm's value. Reflecting the firm's leverage is its current ratio of 2.5, which falls in the top 40% compared with peers globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are cheap.

Conversely, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 1.8%, for example, ranks in the bottom 40% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 08:29:15 · For reference only, not investment advice and not tailored to your situation.